Geode Capital Management LLC boosted its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 11.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,417,389 shares of the company’s stock after buying an additional 140,623 shares during the period. Geode Capital Management LLC’s holdings in Kymera Therapeutics were worth $110,307,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Kymera Therapeutics by 15.6% during the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after buying an additional 845,922 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Kymera Therapeutics by 121.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock valued at $24,535,000 after buying an additional 491,737 shares in the last quarter. Holocene Advisors LP bought a new position in Kymera Therapeutics during the 3rd quarter valued at approximately $47,563,000. Commodore Capital LP bought a new position in Kymera Therapeutics during the 2nd quarter valued at approximately $32,730,000. Finally, UBS Group AG boosted its stake in Kymera Therapeutics by 13.6% during the 4th quarter. UBS Group AG now owns 737,032 shares of the company’s stock valued at $57,348,000 after purchasing an additional 88,314 shares during the last quarter.
Analysts Set New Price Targets
KYMR has been the topic of several recent analyst reports. Canaccord Genuity Group initiated coverage on Kymera Therapeutics in a research note on Wednesday, May 6th. They set a “buy” rating and a $106.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Tuesday, April 21st. Royal Bank Of Canada reiterated an “outperform” rating and set a $108.00 target price on shares of Kymera Therapeutics in a research note on Thursday, February 26th. Citigroup increased their target price on Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Finally, UBS Group increased their target price on Kymera Therapeutics from $90.00 to $128.00 and gave the company a “buy” rating in a research note on Tuesday, March 3rd. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Kymera Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $118.10.
Kymera Therapeutics Price Performance
KYMR stock opened at $74.13 on Friday. The company has a market cap of $6.10 billion, a P/E ratio of -20.76 and a beta of 2.02. Kymera Therapeutics, Inc. has a 1 year low of $36.65 and a 1 year high of $103.00. The stock’s fifty day moving average price is $83.01 and its 200-day moving average price is $79.70.
Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. The firm had revenue of $34.37 million for the quarter, compared to the consensus estimate of $8.27 million. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The company’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same period last year, the business posted ($0.82) EPS. As a group, analysts expect that Kymera Therapeutics, Inc. will post -3.3 earnings per share for the current year.
Insider Transactions at Kymera Therapeutics
In other news, COO Jeremy G. Chadwick sold 91,250 shares of the firm’s stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $77.41, for a total value of $7,063,662.50. Following the transaction, the chief operating officer directly owned 61,202 shares in the company, valued at $4,737,646.82. This trade represents a 59.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Nello Mainolfi sold 30,000 shares of the firm’s stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $81.18, for a total value of $2,435,400.00. Following the completion of the transaction, the chief executive officer owned 666,195 shares in the company, valued at approximately $54,081,710.10. This trade represents a 4.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 260,115 shares of company stock worth $21,218,138. Company insiders own 15.98% of the company’s stock.
About Kymera Therapeutics
Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.
The company’s pipeline emphasizes immunology and oncology.
Read More
- Five stocks we like better than Kymera Therapeutics
- AI Server Earnings: Wall Street Sees One Clear Standout
- Navitas: NVIDIA’s AI Power Broker?
- A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below
- NVIDIA’s New Power Play: Why Fluence Is Surging
Want to see what other hedge funds are holding KYMR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report).
Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
